Cart
sales@molnova.com
CDK4/6/1 Inhibitor
CAS No. 2099128-41-1
CDK4/6/1 Inhibitor( —— )
Catalog No. M32833 CAS No. 2099128-41-1
CDK4/6/1 Inhibitor (Crozbaciclib) is a type of CDK4/6 inhibitor (IC50s: 3 and 1 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 758 | In Stock |
|
| 10MG | 1036 | In Stock |
|
| 25MG | 1568 | In Stock |
|
| 50MG | 2074 | In Stock |
|
| 100MG | 2725 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCDK4/6/1 Inhibitor
-
NoteResearch use only, not for human use.
-
Brief DescriptionCDK4/6/1 Inhibitor (Crozbaciclib) is a type of CDK4/6 inhibitor (IC50s: 3 and 1 nM).
-
DescriptionCrozbaciclib (CDK4/6/1 Inhibitor) is a CDK4/6 inhibitor with IC50s of 3 and 1 nM, respectively.
-
In VitroCrozbaciclib is a potent anti-proliferative agent that arrests U87MG cell line exclusively in G1 (IC50=15.3 ± 2.9 nM in the anti-proliferation assay). Crozbaciclib (13.72 nM; 24 h) significantly increases in the percentage of cells in G1 in U87MG cells.
-
In VivoCrozbaciclib (3.125-50 mg/kg; ) has tumor growth inhibition values ranging from 62% to 99% in an orthotopic xenograft mouse model of glioblastoma multiforme. And Crozbaciclib results insignificant body weight loss. Crozbaciclib increases life span based on the median survival time of vehicle-treated animals in mice is significant at 162%, at a dose of 50 mg/kg.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2099128-41-1
-
Formula Weight488.57
-
Molecular FormulaC28H30F2N6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC=1C2(C=3C(N1)=C(F)C=C(C3)C4=NC(NC5=CC=C(C=N5)C6CCN(C)CC6)=NC=C4F)CCCC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yin L, et al. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy. Eur J Med Chem. 2018 Jan 20;144:1-28.?
molnova catalog
related products
-
BAY 1251152
BAY 1251152 is the first potent, selective, orally available PTEFb/CDK9 inhibitor with biochemical IC50 of 9 nM and MOLM13 cell IC50 of 29 nM.
-
CDK-IN-10
CDK-IN-10 is a cell cycle protein-dependent kinase (CDK) inhibitor with potential anticancer activity for cancer research.
-
AT-7519 trifluoroace...
A potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM).
